This week on The Colosseum, we cover the biggest stories in health, fitness, wellness, and human performance.
The HYROX gold rush is officially underway. Nike entered the hybrid-racing arms race with an entire two-shoe system built specifically around the demands of running fast while still being stable enough for sleds, lunges, and wall balls. The Hybridfly brings ZoomX, a carbon Flyplate, and Zoom Air into a race-day model, while the Hybrid RN serves as the training counterpart. We break down whether Nike has actually solved the hybrid-shoe problem, why Puma's early investment in HYROX may have given it a massive head start, and how Adidas is entering the same fight as nearly every major footwear company tries to claim a piece of one of fitness's fastest-growing categories. From there, we look at UFC lightweight contender Arman Tsarukyan completing his first HYROX less than 24 hours after winning a grappling match, teaming up with former Formula 1 driver Nikita Mazepin to finish in
1:06:39 — another example of just how transferable the conditioning of elite combat athletes can be.
Then we get into a new eight-week bench press study asking a surprisingly practical question: how much should the bar actually slow down before you end a set? Researchers compared different training loads and velocity-loss thresholds in 158 trained men and found that heavier training with more moderate fatigue produced the largest average strength gains, while pushing sets deeper into fatigue produced more muscle growth — but required substantially more repetitions. We break down what bar-speed loss actually means, why grinding every set may be counterproductive if strength is the goal, and how lifters can apply the idea even without expensive velocity-tracking equipment.
Finally, P&G agreed to acquire supplement company Thorne in a $3.8 billion cash deal, raising a bigger question than the price tag: what happens when a brand built largely on practitioner trust, testing standards, and credibility gets absorbed by one of the world's largest consumer-goods companies? We discuss why the acquisition makes sense for P&G, why longtime Thorne customers may be skeptical, and what could happen to that trust if the brand's priorities begin to change. We close by breaking down a viral post linking low-calorie sweeteners with faster cognitive decline, what the underlying observational research can and can't actually prove, and why the headline is much scarier than the conclusion deserves.